LRP4 and myasthenia gravis: In keeping with this classification, we here report anti-LRP4 antibodies in 14,3% of a population of 55 dSN-MG; thus, our contribution confirms the importance of anti-LRP4 detection as a useful diagnostic tool to decrease the percentage of MG (no longer “double” but “triple”) seronegative patients.